Skip to main content

 Scientific publications

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. (Springerplus)

Authors : Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, OShaughnessy J
Year : 2016
Journal : Springerplus
Volume : 5
Pages : 1033

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Authors : Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA
Year : 2016
Journal : Breast Cancer (Auckl)
Volume : 10
Pages : 77-84

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Authors : Morgan G, Aftimos P, Awada A
Year : 2016
Journal : Curr Opin Oncol
Volume : 28(5)
Pages : 441-6

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Authors : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Year : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pages : 463-70

Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.

Authors : Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A, Gil T
Year : 2016
Journal : Mol Clin Oncol
Volume : 4
Pages : 1063-1067

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Authors : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Year : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pages : 947-57

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Authors : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Year : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pages : 364-71

Rare side-effects of checkpoint inhibitors.

Authors : Kourie HR, Awada G, Awada A
Year : 2016
Journal : Curr Opin Oncol
Volume : 28
Pages : 295-305

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Authors : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Year : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pages : 99-108

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Authors : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Year : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Authors : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Hougardy JM, Jochmans K, Mathieu V, Mebis J, Strijbos MH, Vulsteke C, Verheij M
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 7(6)
Pages : 217-23

The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation

Authors : van Dyk N, De Greve J, Schots R, Awada A, Van Eycken L, Geldof T
Year : 2016
Journal : Vlerick business school
Volume : 7
Pages : -

Progressive multifocal leukoencephalopathy mimicking cerebral metastases in a patient treated for nasopharyngeal carcinoma

Authors : Oualla K, Aoun F, Lemort M, Harrouk A, Latifyan S, Awada A, Georgala A
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 10(7)
Pages : 276-280

Do the Guidelines in Oncology Need to Evolve?

Authors : Awada A, Awada G, Hendlisz A
Year : 2016
Journal : Eur Med J
Volume : -
Pages : 15

Adjuvant endocrine therapy in preand perimenopausal women with breast cancer: practice guidelines

Authors : Duhoux F, Neven P, Awada A, Berlière M, Wildiers H, Denys H
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 10(3)
Pages : 92-96

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Authors : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Year : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Authors : Awada A, Penel N, Kotecki N
Year : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Authors : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A
Year : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 691

Rôle de corticostéroïdes dans le cancer de la prostate. Effet bénéfique ou néfaste ?

Authors : Martinez C, Sideris S, Roumeguere T, Van Velthoven R, Awada A, Costante G, Gil T
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Nutrition et prévention du cancer : changer les mentalités

Authors : Awada A
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -